Funded by the German Federal Ministry of Education and Research, the ExploreCOVID project aims to analyze patient history and clinical as well as imaging data across multiple medical centers to identify standardizable diagnostic criteria. By doing so, a comprehensive database of structured data will be established which can be used for future epidemiological insights and the risk stratification of COVID-19 patients.
Current evidence indicates that chest CT imaging may be a valuable tool in the diagnosis, epidemiology, and therapy response evaluation of COVID-19 patients. It offers high sensitivity, short turnaround times, and wide availability. Therefore, chest CT may complement RT-PCR tests, especially in situations of unclear clinical presentation, such as a negative RT-PCR despite strong anamnestic evidence for COVID-19. More importantly, it offers opportunities to assess disease progression directly and may be a method of choice for therapy response assessment in upcoming trials of new therapeutic agents. However, to develop it into a proper instrument, a standardized quantitative approach is required. Additionally, multicentric cooperation is essential to generate a sufficiently large database with a consistently high data quality, which is crucial for modern data mining methods.
All centers involved in this project are provided with access to the COVID-19 functionality within the mint Lesion™ platform. The study centers can conduct structured reads on already available thoracic CT images, extract a wide range of image-based parameters (including radiomics parameters), associate them with other clinical and anamnestic data, and then transfer the resulting structured data to the project partners to identify the parameters relevant for the diagnosis and staging of COVID-19. Despite the very high number of different data sources, this approach guarantees that uniform and homogenous criteria are applied in the data extraction.
The results can be immediately implemented in the mint Lesion™ reading template and distributed worldwide for use in diagnostic procedures and therapy response assessments in clinical trials.
ExploreCOVID: An explorative cohort study to identify optimal CT imaging biomarkers in combination with clinical markers and PCR-RT for the diagnosis and therapy response assessment of COVID-19
Related Resources
Related Resources
New iRECIST Oncologic Response Criteria already in clinical use at the University Medical Center – Tübingen, Germany
Shortly following the release of the new iRECIST- oncologic response criteria (Lancet Oncology, March 2017) the University Medical Center in Tübingen,…
Novel oncologic therapy response criteria (iRECIST and more)
Advances in oncology therapies, such as novel immune-related agents, require adapted and refined criteria and guidelines for the assessment and…
Customized templates in mint Lesion 3.3
mint Lesion™ 3.3 features a novel data and knowledge modelling core that enables you to customize read procedures and reporting templates – or design…